Works cited by this work

262 works

Work: Tumor Microenvironment‐Responsive Nanomedicines for Potentiating Cancer Immunotherapy

Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy
Yanyan Xu, Jingyuan Xiong, Xiyang Sun +1
Review article20222 citations
ABI
Towards precision medicine using biochemically triggered cleavable conjugation
Badri Parshad, Smriti Arora, Balram Singh +4
Review article20252 citations
ABI
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Dunyaporn Trachootham, Jérôme Alexandre, Peng Huang
Review article20092 citations
ABI
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce, Douglas T. Fearon
Review article20152 citations
ABI
Enzyme-responsive nanomaterials for controlled drug delivery
Quanyin Hu, Prateek S. Katti, Zhen Gu
Review article20142 citations
ABI
Analysis of nanoparticle delivery to tumours
Stefan Wilhelm, Anthony J. Tavares, Qin Dai +4
Review article20162 citations
ABI
Reactive‐Oxygen‐Species‐Responsive Drug Delivery Systems: Promises and Challenges
Gurusamy Saravanakumar, Jihoon Kim, Won Jong Kim
Review article20162 citations
ABI
Elements of cancer immunity and the cancer–immune set point
Daniel S. Chen, Ira Mellman
Review article20172 citations
ABI
Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy
Shu Yang, Huile Gao
Review article20172 citations
ABI
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le, Jennifer N. Durham, Kellie N. Smith +43
Article20172 citations
ABI
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles +39
Article20182 citations
ABI
Defining ‘T cell exhaustion’
Christian U. Blank, W. Nicholas Haining, Werner Held +15
Review article20192 citations
ABI
The dose threshold for nanoparticle tumour delivery
Ben Ouyang, Wilson Poon, Yi-Nan Zhang +11
Article20202 citations
ABI
Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy
Satyen H. Gohil, J. Bryan Iorgulescu, David A. Braun +2
Review article20202 citations
ABI
Off-the-Shelf Chimeric Antigen Receptor T Cells
Norihiro Watanabe, Maksim Mamonkin
Review article20212 citations
ABI
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
Zowi R. Huinen, Elisabeth J. M. Huijbers, Judy R. van Beijnum +2
Review article20212 citations
ABI
Modulation of the tumor micro-environment by CD8+ T cell-derived cytokines
Mirjam E. Hoekstra, Saskia V Vijver, Ton N. Schumacher
Review article20212 citations
ABI
In Situ Tumor Vaccination with Nanoparticle Co‐Delivering CpG and STAT3 siRNA to Effectively Induce Whole‐Body Antitumor Immune Response
Worapol Ngamcherdtrakul, Moataz Reda, Molly A. Nelson +11
Article20212 citations
ABI
Hypoxia and the Tumor Microenvironment
Yue Li, Long Zhao, Xiaofeng Li
Review article20212 citations
ABI
Microenvironment‐Responsive Prodrug‐Induced Pyroptosis Boosts Cancer Immunotherapy
Yao Xiao, Tian Zhang, Xianbin Ma +6
Article20212 citations
ABI
Desmoplastic Reaction, Immune Cell Response, and Prognosis in Colorectal Cancer
Naohiko Akimoto, Juha P. Väyrynen, Melissa Zhao +18
Article20222 citations
ABI
NIR/pH-responsive chitosan hydrogels containing Ti3C2/AuNRs with NIR-triggered photothermal effect
Chongchong Liu, Panping Yang, Jingguo Li +2
Article20222 citations
ABI
Reactive oxygen species-responsive polymer drug delivery systems
Jiaxue Liu, Boyan Jia, Zhibo Li +1
Review article20232 citations
ABI
<scp>pH</scp>‐responsive polymers for drug delivery: Trends and opportunities
Jagtar Singh, Pallavi Nayak
Article20232 citations
ABI
The cancer-immunity cycle: Indication, genotype, and immunotype
Ira Mellman, Daniel S. Chen, Thomas Powles +1
Review article20232 citations
ABI